[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"placebo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:placebo":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,75,99,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100439843","early-phase-1-understanding-how-opioids-affect-the-experiential-and-neural-signatures-of-social-experiences-100439843",false,"NCT05007561","Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences","Inclusion Criteria:\n\n* good health\n* English fluency\n* willing to provide contact information for 4-6 close others\n* willing to provide digital photographs of 2 close others\n* own a smartphone\n\nExclusion Criteria:\n\n* presence of medical devices, implants, or other metal objects in or on the body that cannot be removed\n* tattooed eyeliner\n* a body habitus prohibiting MRI scanning\n* claustrophobia\n* self-reported chronic mental or physical illness\n* current and regular use of prescription medication\n* previous history of having difficulty taking pills\n* current use of opioid analgesics\n* depressive symptoms above a 9 on Patient Health Questionnaire\n* excessive alcohol use\n* positive urine drug test\n* body mass index (BMI) greater than 35\n* pregnancy or plans to become pregnant in next 6 months\n* positive urine pregnancy test",true,"ALL","18 Years","25 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The study is a randomized, placebo-controlled design with the opioid antagonist, oral naltrexone. Following random assignment, participants will take 50mg of naltrexone or placebo once a day for 7 days. On days 1 - 7, participants complete reports of their feelings of social connection and mood in order to assess more naturalistic feelings in response to opportunities for social connection outside of the laboratory setting. Additionally, at the end of each day, they complete a physical symptoms questionnaire. On the 7th day, participants will come to the SDSU MRI scanning facility to complete tasks designed to elicit feelings of social connection in the fMRI scanner. After the scan, feelings in response to the scanner tasks will be collected.",[27,28],"Naltrexone","Placebo","RECRUITING","2026-04-08",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":33},"2021-11-16",{"date":37,"type":21},"2027-07",{"name":39,"class":40},"San Diego State University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100532601","neural-mechanisms-of-immersive-virtual-reality-in-chronic-pain-vr-tmd-eeg-100532601","NCT06214923","Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)","Neural Mechanisms of Immersive Virtual Reality in Chronic Pain","VR TMD EEG","Inclusion Criteria:\n\n* Age (18-88 years)\n* English speaker (written and spoken)\n* Temporal Mandibular Disorder (TMD) for at least 3 months\n* TMD Grade Chronic Pain Scale (GCPS) ≥ 0\n\nExclusion Criteria:\n\n* Present or past degenerative neuromuscular disease\n* Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years\n* Cervical pain (e.g. stenosis, radiculopathy)\n* Any personal (or family first degree) history of mania, schizophrenia, or other psychoses\n* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.\n* Use of Antipsychotics (e.g., Risperdal, Ability and clozaril)Lifetime alcohol\u002Fdrug dependence or alcohol\u002Fdrug abuse in past 3 months\n* Pregnancy or breast feeding\n* Color-blindness\n* Impaired or uncorrected hearing\n* Non-dominant hand\n* Any facial trauma that has occurred in the last 6 weeks\n* History of a severe facial trauma in the last 2-3 months\n* Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection)\n* Known history of severe motion sickness\n* Non-removable head cover, artificial hair, certain types of braids or dreadlocks\n* History of fainting\n* History of angioedema\n* Failed drug test (testing for opiates, cocaine, methamphetamines, and amphetamines)","88 Years",{"count":52,"type":21},78,[54],"NA","This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.",[57,58,28,59],"Pain","Virtual Reality","Temporomandibular Disorder",[61,62,63,64],"TMD volunteers","VR","Clinical Pain","Ecological Momentary Assessment","2026-01-22",{"date":67,"type":33},"2026-01-26",{"date":69,"type":33},"2024-04-09",{"date":71,"type":21},"2026-11-30",{"name":73,"class":40},"University of Maryland, Baltimore",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":15,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100608050","effects-of-8-weeks-of-turmeric-ingestion-on-physiology-and-wellbeing-in-healthy-older-adults-100608050","NCT07196514","Effects of 8 Weeks of Turmeric Ingestion on Physiology and Wellbeing in Healthy Older Adults","Exploring the Effects of an 8-week Turmeric Supplementation on Aspects of Physiology and Wellbeing in Healthy Older Adults","Inclusion Criteria:\n\n\\- Body Mass Index between 18.5-39.9.\n\nExclusion Criteria:\n\n* History of, or currently diagnosed with, a cardiovascular disease.\n* Diagnosed with diabetes.\n* Diagnosed with a liver, lung, or kidney disease.\n* Diagnosed with osteoporosis.\n* Diagnosed with dementia.\n* Diagnosed with cancer.\n* Use of medications\u002Fsupplements\u002Fherbal remedies with human evidence of a significant interaction with turmeric.\n* Allergy to turmeric, lemon, black pepper, watermelon, water, pineapple, magnesium or vitamin C.\n* Pregnant, attempting to become pregnant, or breastfeeding.\n* Regular (once per week or more) use of turmeric shots \u002F supplements within the last 3 months.","40 Years","95 Years",{"count":85,"type":21},80,[54],"Curcumin (a bioactive compound found in turmeric) has demonstrated anti-inflammatory and antioxidant properties, and there is evidence to suggest that it may produce improvements in quality of life and markers of health in humans with various conditions. To date, the research has often focussed on the effects of curcumin in human participants with a particular condition. However, turmeric contains hundreds of other bioactive compounds (including other curcuminoids and essential oils) and may be able to benefit a wide range of older adults. Therefore, the aim of this study is to investigate the effects of twice daily consumption of a turmeric beverage for 8-weeks on the physiology and wellbeing of older adults (versus placebo).",[89,28],"Turmeric","2026-01-14",{"date":92,"type":33},"2026-01-16",{"date":94,"type":33},"2025-10-06",{"date":96,"type":21},"2026-07",{"name":98,"class":40},"Nottingham Trent University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":41},"100450459","phase-2-suvorexant-as-an-adjunct-to-buprenorphine-in-persons-who-use-fentanyl-100450459","NCT05145764","Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl","Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl","Inclusion Criteria:\n\n* Aged 18-65\n* Meets DSM-5 criteria for opioid use disorder (OUD) with evidence of physical dependence on opioids\n* Provides a urine sample that tests positive for fentanyl and\u002For fentanyl analogues\n* Interest in being maintained on buprenorphine for OUD\n* Plans to reside in current area for study period\n* Achieving a study maintenance dose of \\>=8mg sublingual buprenorphine\u002Fnaloxone\n* Willing to comply with study protocol\n* Have no clinically significant chronic medical or surgical disorders or conditions that are judged by the investigators to prevent participation\n\nExclusion Criteria:\n\n* Medically contraindicated for buprenorphine, extended-release (XR)-buprenorphine (Sublocade), or suvorexant (as per medication labels)\n* Pregnant or breast feeding\n* Severe Diagnostic and Statistical Manual (DSM)-5 alcohol or benzodiazepine use disorder or evidence of alcohol\u002Fbenzodiazepine physical dependence\n* Have a known allergy to the study medications\n* Past 30-day prescribed use of suvorexant for the indication of insomnia\n* Current benzodiazepine or other prescribed medication for the indication of insomnia\n* Urine sample testing positive for benzodiazepine at screening and admission to residential treatment\n* Current narcolepsy, restless leg syndrome or sleep paralysis\n* High risk for current sleep apnea\n* Current (past 30-day) suicidal behaviors\n* Severe hepatic or renal impairment\n\n  * aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3x upper limit of normal (ULN)\n  * Total bilirubin \\>2x ULN\n  * Creatinine \\>1.5x ULN\n* Past year clinically-significant psychiatric condition judged to interfere with study participation\n* Lack of access to stable housing (necessary for electronic pill dispenser charging)\n* Have circumstances that would interfere with study participation (e.g., impending jail)","65 Years",{"count":108,"type":21},120,[110],"PHASE2","This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine\u002Fnaloxone, followed by a 3-week outpatient phase wherein participants are maintained on sublingual buprenorphine\u002Fnaloxone and transitioned to extended-release buprenorphine).",[113,28,114],"Suvorexant","Opioid Use Disorder",[116,117,113,118,119],"Opioid use disorder","Insomnia","Fentanyl","Buprenorphine","2025-08-07",{"date":122,"type":33},"2025-08-11",{"date":124,"type":33},"2022-03-30",{"date":126,"type":21},"2026-08",{"name":128,"class":40},"Johns Hopkins University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":41},"100567360","phase-1-effects-of-low-intensity-transcranial-magnetic-stimulation-on-major-depressive-disorder-and-on-5-hydroxyindoleacetic-acid-and-brain-derived-neurotrophic-factor-levels-100567360","NCT06667180","Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels","Inclusion Criteria:\n\n* Age between 18 and 60 years.\n* Both sexes.\n* Those who have a diagnosis of MDD previously made by the treating psychiatrist (considering time since diagnosis and recurrence of episodes).\n* Those who continue with their respective treatment and attend follow-up consultations at the health facility.\n* Those who do not have a history of epilepsy, schizophrenia, neurosurgeries.\n* Those who do not have metal plates anywhere in the skull, neck, chest and shoulder.\n* Those who do not use pacemakers.\n* Those who do not take hormone substitutes.\n* Those who agree to participate in the research.\n\nExclusion Criteria:\n\n* Those who are pregnant.","60 Years",{"count":137,"type":21},40,[139,110],"PHASE1","The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived neurotrophic factor (BDNF). TMS works to treat MDD by using low-intensity magnetic fields to modulate certain areas of the brain, activating them which can help improve the mood of those suffering from the disorder. Final metabolites of serotonin such as 5-HIAA and growth factors such as BDNF will also be studied before starting the intervention and at the end to check if there is a significant change in their concentration. Likewise, its safety will be evaluated by monitoring the symptoms that they present at the end of the intervention and one month later. The main questions that are intended to be answered are:\n\n* Does low-intensity TMS reduce depressive symptoms in patients with MDD?\n* Does low-intensity TMS significantly change the initial and final concentrations of 5-HIAA and BDNF?\n* What adverse effects might patients who are exposed to low-intensity TMS experience? The researchers will compare low-intensity and accelerated TMS with sham TMS to see if low-intensity TMS works to treat MDD.\n\nParticipants:\n\n* Will undergo an initial clinical assessment to confirm the disorder, comorbidities, and general health status.\n* A 5 mL blood sample will be taken before starting the intervention.\n* Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 milliTesla (mT) and frequency of 50 Hz in theta bursts. Symptoms will be monitored daily.\n* A 5 mL blood sample will be taken at the end of the intervention and general health status clinimetrics will be reapplied.",[142,143,28],"Depression - Major Depressive Disorder","Transcranial Magnetic Stimulation",[145,146,147,148,149],"accelerated low-intensity transcranial magnetic stimulation","Major depressive disorder","depression","brain-derived neurotrophic factor","5-hydroxyindoleacetic acid","2025-05-05",{"date":152,"type":33},"2025-05-08",{"date":154,"type":33},"2024-10-28",{"date":156,"type":21},"2025-08-26",{"name":158,"class":40},"Universidad de Guanajuato"]